Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJerry LeeAAAimaz AfroughVHVanna Hovanky

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals poor progression-free survival in relapsed multiple myeloma with IEC-HS after ide-cel and cilta-cel therapies.

Key Points

  • This research aims to analyze the real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in multiple myeloma patients.
  • Retrospective multi-institutional analysis from 15 centers
  • Included patients with relapsed/refractory multiple myeloma
  • Defined IEC-HS based on diagnostic criteria
  • Utilized Kaplan-Meier and logistic regression analyses
  • 74 out of 1502 patients diagnosed with IEC-HS (4.9%)
  • Median progression-free survival of 6.5 months with cilta-cel and 8.9 months with ide-cel for IEC-HS
  • Increased rates of cytopenias, renal insufficiency, and pulmonary involvement observed in IEC-HS patients
  • IEC-HS associated with poorer overall survival (median OS of 9.6 months for cilta-cel)

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4cchttps://doi.org/10.1182/blood-2025-719
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study2026
  2. 2Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.2026
  3. 3Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, high-risk factors, and management2026 · 1 citations
  4. 4A novel immune signature characterized by activation of the IFNγ-IL18 axis identifies immune effector cell-associated HLH-like syndrome after CD22 chimeric antigen receptor T-cell therapy2025
  5. 5Outcomes of patients who received CAR T cell therapy and developed IEC-HS treated with cytokine directed therapy.2024 · 1 citations